Short-Term Indicators Showing Strength for Boston Scientific Corporation (BSX)

Pierce David A, EVP,Pres MedSurg, subtracted 5,000 shares of Boston Scientific Corporation (BSX) from its portfolio at the rate of $42.50 per share valuing $212,500 on Sep 03. The insider left behind 24,201 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. Boston Scientific Corporation (BSX) stock has lost $0.12, or -0.54%, in the past five days. In the last full month, these shares have gained $1.25, or 3.02%. In the past three months, this stock’s price has risen by $2.60, or 6.50%. This year-to-date, Boston Scientific Corporation (BSX) shares have gained $7.27, or 20.57%.

Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Boston Scientific Corporation (BSX) stock, 50% of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, 100% of medium-term indicators point to this stock being a “ Buy .” Looking further ahead, 100% of long-term indicators suggest that this stock is a “ Buy .”

With 1,392,973 K shares outstanding, this company currently has a market capitalization of $59,354,580K. Boston Scientific Corporation (BSX) generates $9,823 M in annual sales, amounting to annual net income of $1,671 M. This stock has generated a 1-Year Total Return of 19.19%, a 3-Year Total Return of 81.24%, and a 5-year Total Return of 240.88%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.


For the current fiscal quarter, which is set to end in 09/2019, the average earnings estimate is $0.38 per share. This estimate came from a total of 11 Wall Street Analysts. Of those market experts, the high estimate was $0.39 and the low estimate was $0.35. In the year-ago quarter, Boston Scientific Corporation (BSX) generated per-share earnings of $0.35. If the analysts are correct about the current quarter’s earnings, the growth will be +8.57% .

Turning our focus now to insider trading activity, there have been 5 purchases (50,948 shares in total) and 9 sale (85,710 shares in total) in the last 3 months. In the last 6 months, there have been 22 insider buys amounting to 160,043 shares and 32 insider sales amounting to 363,975 shares. In the past full year, 138 insider purchases were made (involving 1,492,913 shares) and 172 insider sell-offs equivalent to 1,632,891 shares.

Moving onto liquidity, Boston Scientific Corporation (BSX) has a Current Ratio of 0.76, a Quick Ratio of 0.54 and a Cash Ratio of 0.15. Looking at this company’s capital structure, its Total Debt to Total Equity is 80.86, its Total Debt to Total Capital is 44.71, and its Total Debt to Total Assets is now 33.60. Looking even further ahead into the future, its Long-Term Debt to Equity is 6.46 and its Long-Term Debt to Total Capital is 55.04.